Sanofi extends its Pompe range with first Nexviazyme OKSanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its Share XSanofi extends its Pompe range with first Nexviazyme OKhttps://pharmaphorum.com/news/sanofi-extends-its-pompe-range-with-first-nexviazyme-ok/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
Sanofi’s venglustat bombs again, but isn’t dead yetShortly after failing a Parkinson’s disease study, Sanofi’s venglustat has missed the mark in another trial in autosomal Share XSanofi’s venglustat bombs again, but isn’t dead yethttps://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/
Switch data back Chiesi/Protalix long-acting Fabry drugChiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, Share XSwitch data back Chiesi/Protalix long-acting Fabry drughttps://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/
Finding agility in unprecedented timesNicole Farmer, general manager, UK & Ireland at Sanofi Genzyme, tells us how the company aimed for agile Share XFinding agility in unprecedented timeshttps://deep-dive.pharmaphorum.com/magazine/patients-and-partnerships-2020/finding-agility-in-unprecedented-times/
Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and BrexitMarc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for Share XSanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexithttps://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/
